초록 ▼

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HB

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.

대표청구항 ▼

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HB

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. rein the foreign protein enhances the insecticidal activity of the recombinant with respect to wild type when the foreign protein is expressed in insect cells infected therewith. 6. The nuclear polyhedrosis virus as in claim 2 wherein the nuclear polyhedrosis virus is Autographa californica nuclear polyhedrosis virus. 7. A recombinant baculovirus wherein the virus is Autographa californica nuclear polyhedrosis virus, which in insect cells infected therewith, expresses an AaIT toxin, or a functional derivative thereof, by secretion. 8. A method of preparing nuclear polyhedrosis viruses with an intact polyhedrin gene and an improved insect control property, comprising: cloning a chimeric gene encoding an insecticidal toxin, the toxin being a foreign protein to an insect host, the chimeric gene comprising a genetic sequence coding for the toxin, or a functional derivative thereof, and a signal peptide, into a baculovirus transfer vector at a restriction site down stream of a promotor; and introducing the chimeric gene into the genome of a nuclear polyhedrosis virus without disrupting the polyhedrin gene, wherein the chimeric gene when expressed in the insect host provides improved toxicity with respect to the wild type nuclear polyhedrosis virus. 9. The method as in claim 8 wherein the toxin is AaIT. 10. The method as in claim 8 or 9 wherein the baculovirus is Autographa californica nuclear polyhedrosis virus. 11. The method as in claim 10 wherein the improved insect control property is an increased kill rate with respect to wild type baculovirus. 12. The method as in claim 10 wherein the improved insect control property is more rapid onset of feeding cessation. 13. A method for enhancing the toxicity of a nuclear polyhedrosis virus, comprising: isolating a recombinant DNA molecule having a genetic sequence coding for an insect-selective protein neurotoxin; and introducing the recombinant DNA molecule into the genome of the nuclear polyhedrosis virus without disrupting the polyhedrin gene, wherein the insect-selective protein neurotoxin provides enhanced toxicity when expressed in insect cells infected therewith with respect to wild-type. 14. The method as in claim 13 wherein the genetic sequence coding for an insect-selective protein neurotoxin is derived from venom. 15. The method as in claim 14 wherein the venom is derived from scorpions, wasps, snails, or spiders. 16. The recombinant nuclear polyhedrosis virus as in claim 1 or 4 wherein the recombinant is a hybrid having a host range expanded with respect to wild type virus. 17. The recombinant nuclear polyhedrosis virus as in claim 5 wherein the infection is via oral ingestion of the recombinant by insects.